Severity
Moderate
FDA Drug recall · Reported December 26, 2018
Superpotent Drug: recalled lots may have higher concentration of ibuprofen.
Tris Pharma Inc. recalled infants* IBUPROFEN, Concentrated Ibuprofen Oral Suspension, USP (NSAID), 50 mg per 1.25 m… - a moderate-severity action.
infants* IBUPROFEN, Concentrated Ibuprofen Oral Suspension, USP (NSAID), 50 mg per 1.25 m… was recalled by Tris Pharma Inc. in December 26, 2018. Reason: Superpotent Drug: recalled lots may have higher concentration of ibuprofen.. Check the official notice for the remedy. Verify recall #D-0335-2019 with the FDA Drug before acting.
The recall
Tris Pharma Inc. issued this moderate-severity FDA Drug recall-Superpotent Drug: recalled lots may have higher concentration of ibuprofen..
Sourced from official FDA Drug enforcement records. Verify recall #D-0335-2019 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0335-2019) was formally reported on December 26, 2018, with the manufacturer initiating the action on November 26, 2018. It is classified under Moderate severity (Class II), with a current status of Terminated. Tris Pharma Inc. is listed as the recalling firm, operating out of Monmouth Junction, NJ. Federal records list the affected scope as 164,304 bottles.
The documented reason for this recall is: Superpotent Drug: recalled lots may have higher concentration of ibuprofen. Distribution data in the federal record shows the product reached: One distributor in PA who further distributed Nationwide in the USA.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
164,304 bottles
Related Recalls
6
5 from same agency
infants* IBUPROFEN, Concentrated Ibuprofen Oral Suspension, USP (NSAID), 50 mg per 1.25 mL, Dye-Free Berry Flavor, 0.5 FL OZ (15 mL) bottle, Distributed by Wal-Mart Stores, Inc., Bentonville, AR 72716, NDC 49035-125-23, UPC 0 78742 02016 7.
Superpotent Drug: recalled lots may have higher concentration of ibuprofen.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0335-2019 |
| Date reported | December 26, 2018 |
| Date initiated | November 26, 2018 |
| Recalling firm | Tris Pharma Inc. |
| Firm location | Monmouth Junction, NJ |
| Affected scope | 164,304 bottles |
| Distribution | One distributor in PA who further distributed Nationwide in the USA. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported December 26, 2018. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.